Ross Merrick I
Department of Surgical Oncology, University of Texas M. D. Anderson Cancer Center, 1400 Holcombe Boulevard, Unit #444, Houston, TX 77030, USA.
Surg Oncol Clin N Am. 2006 Apr;15(2):341-52. doi: 10.1016/j.soc.2005.12.013.
Accurate melanoma staging is critical in establishing management strategies and estimating disease relapse. Combined with assessment of comorbidities and understanding treatment toxicities, risk assessment is central to offering appropriate surgical or systemic therapies. The American Joint Commission on Cancer (AJCC) melanoma staging system provides survival estimates within anatomically defined disease categories. Newer prognostic factors and methods of prognostic analyses can augment predictions for the presence of micro-metastatic disease and further define the risk for relapse. This article highlights relevant changes, evidence supporting future incorporation of more recently defined prognostic variables, novel approaches used as adjuncts to the current staging system, and future directions of the AJCC staging committee.
准确的黑色素瘤分期对于制定治疗策略和评估疾病复发至关重要。结合合并症评估和对治疗毒性的了解，风险评估是提供适当手术或全身治疗的核心。美国癌症联合委员会（AJCC）黑色素瘤分期系统在解剖学定义的疾病类别中提供生存估计。更新的预后因素和预后分析方法可以增强对微转移疾病存在的预测，并进一步定义复发风险。本文重点介绍了相关变化、支持未来纳入最近定义的预后变量的证据、作为当前分期系统辅助手段的新方法以及AJCC分期委员会的未来方向。
